Brief: Roche Receives FDA's Approval For Its Enspryng, A First-In-Class IL-6R Inhibitor
16/10/2026 06:02
BRIEF-Roche Receives FDA's Approval For Its Enspryng, A First-In-Class IL-6R Inhibitor Oct 16 (Reuters) - ROCHE HOLDING AG ROPC.S:
FDA APPROVES ROCHE’S ENSPRYNG, A FIRST-IN-CLASS IL-6R INHIBITOR, AS THE FIRST AND ONLY AT-HOME SUBCUTANEOUS TREATMENT OPTION FOR THYROID EYE DISEASE (TED)
ROCHE HOLDING AG - ENSPRYNG OFFERS FIRST AT-HOME SUBCUTANEOUS TREATMENT OPTION FOR TED
ROCHE HOLDING AG - FDA APPROVAL BASED ON PHASE III SATRAGO-1 AND -2 STUDIES
ROCHE HOLDING AG - TED AFFECTS ABOUT 155 OUT OF EVERY 100,000 PEOPLE IN THE US
Source text: ID:nGNE4Rr2sP
Further company coverage: ROPC.S
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey